Update on use of aldesleukin for treatment of high-risk metastatic melanoma

High-dose interleukin-2 has been used for the treatment of metastatic melanoma since 1998 based on data proving durable complete responses in up to 10% of treated patients. The immunomodulatory effects of this critical cytokine have been instrumental in the development of immunotherapy for melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Amaria, Rodabe N, Reuben, Alexandre, Cooper, Zachary A, Wargo, Jennifer A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918260/
https://www.ncbi.nlm.nih.gov/pubmed/27471714
http://dx.doi.org/10.2147/ITT.S61590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918260/
https://www.ncbi.nlm.nih.gov/pubmed/27471714
http://dx.doi.org/10.2147/ITT.S61590

Ejemplares similares